Literature DB >> 22216993

Use and misuse of opioid replacement therapies: a Queensland study.

Andrew Smirnov1, Robert Kemp.   

Abstract

Buprenorphine/naloxone has recently been introduced in Australia and is available for unsupervised dosing within Queensland. A retrospective observational study of data collected during 2000-2007 for clients obtaining injecting equipment from the Brisbane Harm Reduction Centre in Queensland is presented. The numbers of service occasions and needles and syringes were used as surrogate drug use measures. Buprenorphine and naloxone were misused at lower rates when compared with buprenorphine and methadone. Furthermore, the misuse of opioid replacement therapies represented less than 5% of all illicit opioid injections. Implications and study limitations are discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22216993     DOI: 10.3109/10826084.2011.629017

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  3 in total

1.  Buprenorphine treatment for narcotic addiction: not without risks.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

2.  Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities.

Authors:  Björn Johnson; Torkel Richert
Journal:  Harm Reduct J       Date:  2019-05-02

3.  Remote buprenorphine-naloxone initiation as an essential service for people with chronic pain and opioid dependence during the COVID-19 pandemic: Case reports, clinical pathways, and implications for the future.

Authors:  Hance Clarke; Aliza Weinrib; Yuvaraj Kotteeswaran; Joel Katz; Alvis Yu; Robert Tanguay
Journal:  Can J Pain       Date:  2020-09-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.